Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer
Status:
Active, not recruiting
Trial end date:
2021-05-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of the
combination vorinostat given in combination with either sirolimus, everolimus or temsirolimus
that can be given to patients with advanced cancer. The safety of this drug combination will
also be studied.
The Study Drugs:
Vorinostat is designed to prevent or slow down the growth of cancer cells by blocking
proteins.
Everolimus is designed to stop cells from dividing. This may stop or slow the growth or
spread of cancer cells.
Temsirolimus is designed to block a protein called mTOR (a protein that is thought to cause
cancer cells to grow) inside the cancer cell. This may interfere with the growth or spread of
cancer cells or possibly kill them.
Sirolimus is designed to block a protein called mTOR inside the cancer cell. This may
interfere with the growth or spread of cancer cells or possibly kill the cancer cells.
This is an investigational study. Sirolimus is FDA approved and commercially available as an
anti-rejection drug for kidney transplant recipients. Everolimus is FDA-approved and
commercially available for the treatment of pancreatic neuroendocrine tumor, subependymal
giant cell astrocytoma, and renal cell carcinoma. Temsirolimus is FDA approved and
commercially available for the treatment of renal cell carcinoma. Vorinostat is FDA approved
and commercially available for the treatment of cutaneous T-cell lymphoma. The combination of
these drugs is investigational.
Up to 249 patients will take part in this study. All will be enrolled at MD Anderson.